Use of Enos Transcription Enhancers in the cell therapy of ischemic heart disease

摘要

Use of compounds that enhance the transcription of endothelial nitric oxide synthase (ENOS) to treat stem cells and stem cell therapy in patients with ischemic heart diseases such as heart disease or ischemic cardiomyopathy.The Treatment of such cells which are isolated, for example, Bone Marrow, with Enos Transcription Enhancer before Administration increases its functional activity and improves neovascularization of the heart and Cardiac Regeneration.Claim 3: Use according to claim 1 and / or claim 2, the breeder in the transcription of endothelial nitric oxide synthase is selected from 4 - fluoro - N - (2 - indan - il) benzamide and indan ilamida acid - 2 - 2.2 - difluorobenzo [1,3] dioxol - 5 - carboxylic acid.Claim 8: a procedure to produce a Medicament for treating stem cells and / or stem cell therapy in a patient with ischemic heart disease, which comprises employing an Enhancer of Transcription of endothelial nitric oxide synthase.A Medicine for treating claim 10: stem cells and / or stem cell therapy in a patient with ischemic heart disease, comprising an Enhancer of Transcription of endothelial nitric oxide synthase.